Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.35 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.35 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.34 |
| ▸ | STAT3 | P40763 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.32 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10180156 | 0.89 | STAT3 (0.35) | EGLN1STAT3PRMT5GPR119 | |
| SCHEMBL10181903 | 0.88 | FASN (0.35) | GUCY1A1GUCY1B1EGLN1STAT3PRMT5 | |
| SCHEMBL10181919 | 0.87 | USP5 (0.35) | EGLN1PRMT5CYP3A5 | |
| SCHEMBL10181366 | 0.87 | PRMT5 (0.33) | STAT3PRMT5GPR119 | |
| SCHEMBL10179970 | 0.85 | THRB (0.41) | STAT3PRMT5 | |
| SCHEMBL10179966 | 0.85 | THRB (0.41) | STAT3PRMT5 | |
| SCHEMBL10187803 | 0.83 | FASN (0.36) | STAT3PRMT5GPR119 | |
| SCHEMBL10179883 | 0.83 | DRD2 (0.36) | PRMT5GPR119 | |
| SCHEMBL10180803 | 0.82 | STAT3 (0.36) | STAT3PRMT5 | |
| SCHEMBL10180322 | 0.81 | PRMT5 (0.35) | EGLN1STAT3PRMT5GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | NR1I2 160/4885CACNA1B 763/4885NR1H2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.